OPKO Health and Entera Bio, a developer of oral peptides and protein replacement therapies, entered into a license agreement to advance into the clinic the first oral dual agonist GLP-1/glucagon peptide as a once-daily tablet treatment for patients with obesity, metabolic, and fibrotic disorders.  The program combines OPKO’s oxyntomodulin analog (OPK-88006) and Entera’s N-Tab technology. The companies expect to file an Investigational New Drug application with the U.S. Food and Drug Administr...